Skip to content
Inciteful Med

Advanced Risk Stratification (ELN Guidelines)

Last updated:

The ELN 2022 Guidelines classify Acute Myeloid Leukemia (AML) into favorable, intermediate, or adverse risk groups based on your specific genetic mutations. This risk stratification helps your oncology team determine if you need standard chemotherapy or an allogeneic stem cell transplant.

Key Takeaways

  • • The ELN 2022 guidelines classify AML into favorable, intermediate, and adverse risk categories based on DNA mutations and chromosomes.
  • • Favorable risk patients often achieve long-term remission with chemotherapy alone, while intermediate and adverse risk patients may need stem cell transplants.
  • • Under the 2022 updates, the FLT3-ITD mutation is now broadly classified as intermediate risk, and CEBPA mutations must be specifically in the bZIP domain to be favorable.
  • • Risk categories are based on large population statistics and cannot guarantee an exact outcome for any individual patient.
  • • Your initial risk category is only a starting point, and your treatment plan may change based on your measurable residual disease (MRD) response to initial therapy.

When you and your doctor look at your pathology report, one of the most important goals is to determine your risk stratification. This is a process where doctors use your specific genetic “fingerprint” to predict how likely the leukemia is to respond to treatment and stay in remission [1].

The gold standard for this process is the ELN (European LeukemiaNet) 2022 Guidelines [2]. These guidelines help your care team decide how intensive your treatment should be—for example, whether you can be treated with chemotherapy alone or if you will likely need an allogeneic stem cell transplant (using cells from a donor) in your first remission [3][4].

The Three Risk Categories

The ELN system groups patients into three broad categories based on their chromosomes and DNA mutations:

  • Favorable Risk: This group has the highest probability of achieving a long-term remission with intensive chemotherapy [3]. Key markers include:
    • Core-Binding Factor (CBF) leukemias (specific translocations like t(8;21) or inv(16)) [1].
    • NPM1 mutation (when it occurs without an FLT3-ITD mutation) [5].
    • CEBPA mutation, specifically when it is located in the bZIP domain of the gene [6][7].
  • Intermediate Risk: This is a broad group where the outcome is less predictable. These patients are often candidates for a stem cell transplant if their leukemia doesn’t disappear completely after the first round of treatment [8][9]. This group now includes patients with an FLT3-ITD mutation (provided they do not also have any adverse-risk genetic features), regardless of how many mutated cells are present [8][1].
  • Adverse Risk: This group has a higher risk of the leukemia returning or not responding to standard chemotherapy [10]. These patients are typically prioritized for clinical trials and early stem cell transplants [11][12]. Key markers include:
    • TP53 mutation [13].
    • Complex Karyotype (having 3 or more unrelated chromosomal abnormalities) [14][1].
    • Myelodysplasia-Related (MR) Genes: A specific list of nine genes (including ASXL1, RUNX1, and SF3B1) that are often seen in leukemias that evolved from other blood disorders [15][16].

Significant Changes in 2022

The 2022 guidelines made several major updates to improve accuracy. One of the biggest changes involves FLT3-ITD. In the past, the “strength” of this mutation (called the allelic ratio) determined your risk. Now, the 2022 guidelines have simplified this: if you have FLT3-ITD, you are generally classified as Intermediate Risk (assuming no other adverse genes), regardless of the ratio or whether you also have an NPM1 mutation [8][1].

Additionally, the criteria for the CEBPA mutation became more strict. It is no longer enough to just have the mutation; it must specifically be an “in-frame bZIP domain mutation” to be considered favorable [17][7].

Important Limitations

While the ELN categories are incredibly helpful for planning, they are not a “crystal ball.” They have some important limitations:

  • Population vs. Individual: These categories are based on statistics from thousands of patients [8]. They tell you what usually happens, not what will happen to you specifically.
  • Age and Fitness: The ELN system was originally designed for patients who are healthy enough for intensive chemotherapy [18][19]. For older adults or those with other health conditions (comorbidities), these categories may not be as accurate [20].
  • The “MRD” Factor: Your risk category is determined at the start, but your Measurable Residual Disease (MRD)—how your leukemia actually responds to the first month of treatment—is often a more powerful predictor of your long-term outcome than your initial risk group [21][22].

Risk stratification is a starting point, not a final destination. Your team will continuously update your plan as they see how your unique leukemia responds to therapy [2][23].

Frequently Asked Questions

What are the three AML risk categories in the ELN guidelines?
The European LeukemiaNet (ELN) guidelines divide AML into favorable, intermediate, and adverse risk groups based on your genetic markers. These categories help your doctor predict how well the leukemia will respond to treatment and guide your overall care plan.
What does an intermediate risk score mean for my AML treatment?
Intermediate risk means the outcome of standard chemotherapy is less predictable. Patients in this category are often candidates for a stem cell transplant if their leukemia does not completely disappear after the first round of treatment.
How does the FLT3-ITD mutation affect my AML risk group?
Under the updated 2022 ELN guidelines, having an FLT3-ITD mutation generally places you in the intermediate risk category. This applies regardless of the mutation ratio, as long as there are no other adverse genetic features present.
What is MRD and why is it important for my prognosis?
MRD stands for Measurable Residual Disease, which measures how your leukemia actually responds to the first month of treatment. How your body responds to therapy is often a more powerful predictor of your long-term outcome than your initial ELN risk category.

Questions for Your Doctor

  • • Based on the ELN 2022 guidelines, which specific category—Favorable, Intermediate, or Adverse—does my leukemia fall into?
  • • If I have an NPM1 mutation, do I also have an FLT3-ITD mutation? How does that combination affect my 'Intermediate' risk status?
  • • For my CEBPA mutation, is it located specifically in the 'bZIP' domain? Why is that detail important for my prognosis?
  • • Are any 'myelodysplasia-related' (MR) genes, such as ASXL1 or RUNX1, present in my results?
  • • Given my risk group, is an allogeneic stem cell transplant recommended in my first remission, or can we consider chemotherapy alone?

Questions for You

  • • How do I feel about the possibility of a stem cell transplant if my results are in the 'Intermediate' or 'Adverse' categories?
  • • Do I understand that these 'risk groups' are based on large groups of people and not a guaranteed outcome for me specifically?
  • • Am I comfortable with the idea that my treatment plan might change based on how my body responds to the first round of chemotherapy (my 'MRD' status)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.

    Lachowiez CA, Long N, Saultz J, et al.

    Blood advances 2023; (7(9)):1899-1909 doi:10.1182/bloodadvances.2022009010.

    PMID: 36441905
  2. 2

    Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.

    Falini B, Dillon R

    Blood cancer discovery 2024; (5(1)):8-20 doi:10.1158/2643-3230.BCD-23-0144.

    PMID: 37917833
  3. 3

    Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.

    Sakaguchi M, Yamaguchi H, Najima Y, et al.

    Blood advances 2018; (2(20)):2744-2754 doi:10.1182/bloodadvances.2018020305.

    PMID: 30341082
  4. 4

    Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group.

    Wen Q, Jiang C, Liu X, et al.

    Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2025; (37(3)):417-431 doi:10.21147/j.issn.1000-9604.2025.03.10.

    PMID: 40642494
  5. 5

    Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: a systematic review and meta-analysis.

    Chang YS, Lee YW, Liu CY, et al.

    Haematologica 2026; doi:10.3324/haematol.2025.288081.

    PMID: 41742883
  6. 6

    Location, location, location: A mini-review of CEBPA variants in patients with acute myeloid leukemia.

    Faisal MS, Sung PJ

    Leukemia research reports 2023; (20()):100386 doi:10.1016/j.lrr.2023.100386.

    PMID: 37680323
  7. 7

    CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.

    Tien FM, Hou HA

    International journal of hematology 2024; (120(5)):541-547 doi:10.1007/s12185-024-03773-5.

    PMID: 38671183
  8. 8

    Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project.

    Pinar IE, Celik S, Polat MG, et al.

    BMC cancer 2025; (25(1)):1546 doi:10.1186/s12885-025-14987-z.

    PMID: 41073967
  9. 9

    Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

    Hernández-Sánchez A, Villaverde Ramiro Á, Sträng E, et al.

    Leukemia 2026; (40(2)):418-428 doi:10.1038/s41375-025-02851-9.

    PMID: 41535568
  10. 10

    Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.

    Issa GC, Zarka J, Sasaki K, et al.

    Blood cancer journal 2021; (11(9)):162 doi:10.1038/s41408-021-00557-6.

    PMID: 34588432
  11. 11

    Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

    Badar T, Atallah E, Shallis R, et al.

    Leukemia 2023; (37(4)):799-806 doi:10.1038/s41375-023-01847-7.

    PMID: 36807649
  12. 12

    Allogeneic transplantation in adverse-risk acute myeloid leukemia: Challenges, strategies, and future directions.

    Huang J, Wu X, Wang G, et al.

    Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2025; (37(5)):718-736 doi:10.21147/j.issn.1000-9604.2025.05.05.

    PMID: 41229979
  13. 13

    Proposed Refinement of 2022 European LeukemiaNet Adverse-Risk Group of AML Patients Using a Real-World Cohort.

    Wangulu C, Zhao D, Zhou Q, et al.

    Cancers 2025; (17(9)) doi:10.3390/cancers17091405.

    PMID: 40361333
  14. 14

    TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

    Haase D, Stevenson KE, Neuberg D, et al.

    Leukemia 2019; (33(7)):1747-1758 doi:10.1038/s41375-018-0351-2.

    PMID: 30635634
  15. 15

    Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

    Bill M, Eckardt JN, Döhner K, et al.

    Leukemia 2026; (40(1)):63-71 doi:10.1038/s41375-025-02781-6.

    PMID: 41145671
  16. 16

    Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.

    Sargas C, Ayala R, Larráyoz MJ, et al.

    Blood cancer journal 2023; (13(1)):77 doi:10.1038/s41408-023-00835-5.

    PMID: 37173322
  17. 17

    AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

    Zhao D, Zhou Q, Zarif M, et al.

    Leukemia research 2023; (134()):107376 doi:10.1016/j.leukres.2023.107376.

    PMID: 37690321
  18. 18

    Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.

    Chen E, Jiao C, Yu J, et al.

    Cancer medicine 2023; (12(24)):21615-21626 doi:10.1002/cam4.6696.

    PMID: 38098254
  19. 19

    Tailoring intensive and less-intensive treatment in acute myeloid leukemia.

    Seeling C, Ganser A, Döhner H, Kühn MWM

    Seminars in hematology 2025; (62(3)):196-208 doi:10.1053/j.seminhematol.2025.09.001.

    PMID: 41093668
  20. 20

    Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia.

    Park S, Kim TY, Cho BS, et al.

    Haematologica 2024; (109(4)):1095-1106 doi:10.3324/haematol.2023.283606.

    PMID: 37706344
  21. 21

    Who Should Receive an Allogeneic Transplant in First Complete Remission?

    Ribera JM, Genescà E, Ribera J

    Clinical lymphoma, myeloma & leukemia 2020; (20 Suppl 1()):S48-S51 doi:10.1016/S2152-2650(20)30459-6.

    PMID: 32862866
  22. 22

    Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.

    Huang J, Xia Y, Xiang M, et al.

    Transplantation and cellular therapy 2025; doi:10.1016/j.jtct.2025.12.951.

    PMID: 41423033
  23. 23

    Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

    Hoff FW, Blum WG, Huang Y, et al.

    Blood advances 2024; (8(20)):5297-5305 doi:10.1182/bloodadvances.2024013685.

    PMID: 39110987

This page explains AML risk stratification and the ELN 2022 guidelines for educational purposes only. Always discuss your specific pathology results and treatment plan with your oncologist.

Stay up to date

Get notified when new research about Acute myeloid leukemia is published.

No spam. Unsubscribe anytime.